Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

US8968740B2 · kind B2 · utility

Assignees

• DANA-FARBER CANCER INSTITUTE, INC. · US
• The Brigham and Women's Hospital, Inc. · US
• CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) · AR
• Staples, Inc. · US

Inventors

• Margaret A. Shipp · Wellesley, US
• Jing Ouyang · East Sharon, US
• Kunihiko Takeyama · Kyoto, JP
• Jeffery L. Kutok · Natick, US
• Scott J. Rodig · Westwood, US
• Gabriel Rabinovich · Dieciséis de Julio, AR
• Diego Omar Croci Russo · Tortuguitas, AR
• Mariana Salatino · Dieciséis de Julio, AR

Key dates

• Filing date: Nov 12, 2010
• Grant date: Mar 3, 2015
• Expiry date: Nov 12, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.